Dialysis product manufacturer NxStage Medical Inc. has created a new scientific advisory board led by Allan J. Collins, MD, who will act as the senior medical advisor.
Board members and affiliations include:
- Allan Collins, MD – Senior Medical Advisor of NxStage Medical, Inc.
- Chris Chan, MD – University Health Network, Toronto, Canada
- Michael A. Kraus, MD – Indiana University School of Medicine, Clarian Health
- Peter McCullough, MD – Baylor University Medical Center
- José Morfin, MD – UC Davis School of Medicine
- John Burkart, MD – Wake Forest University Medical Center
- Mike Copland, MD – University of British Columbia, Vancouver General Hospital
- Richard Fluck, MD – Royal Derby Hospital, Derby, United Kingdom
- Sheru Kansal, MD – Cleveland Clinic
- Paul Komenda, MD – Seven Oaks General Hospital, Winnipeg, Canada
- George Bakris, MD – University of Chicago Medicine
This new panel will seek to highlight the benefits of HHD therapy and advance the quality of dialysis care, NxStage said. The group will also advise NxStage on other focus items in its innovation pipeline, specifically with new perspectives related to peritoneal dialysis and alternative treatment applications.
“NxStage's selection of outstanding clinical leaders to develop critical impactful data is a major step toward enhancing access to this differentiated therapy option,” said Collins. “NxStage is committed to significant innovation in dialysis care, and the impact its technologies can and will have are life-changing. It’s an honor that this prestigious group of nephrologists and cardio renal experts from around the world has chosen to join me in this important role. Through extensive clinical research, we expect to demonstrate the benefits of these advancements and help to guide further innovation needed so that we may advance patient care.”
“Over the years, we’ve shown that HHD with the System One is not just another home alternative, but a differentiated therapy with clinically significant benefits,” said NxStage president, Joe Turk. ”Our trusted clinician advisors have always served a critical role in helping to define the data we need to show and how these may be communicated to advance therapy adoption. We thank our outgoing board for their years of commitment, and are incredibly excited to benefit from this new board’s diverse experience and unique backgrounds in the years to come.”